GLENMARK:NSE:NSE-Glenmark Pharmaceuticals Limited (INR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 1230.6

Change

-10.65 (-0.86)%

Market Cap

USD 343.22B

Volume

0.54M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-21 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

+10.70 (+0.72%)

USD 3,520.42B
DIVISLAB:NSE Divi's Laboratories Limited

+19.75 (+0.44%)

USD 1,204.18B
ZYDUSLIFE:NSE Zydus Lifesciences Limited

-8.60 (-0.80%)

USD 1,116.46B
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

+23.45 (+0.39%)

USD 1,006.15B
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

-10.00 (-0.35%)

USD 958.22B
MANKIND:NSE Mankind Pharma Ltd

-36.80 (-1.70%)

USD 877.19B
LUPIN:NSE Lupin Limited

-7.90 (-0.50%)

USD 711.68B
AUROPHARMA:NSE Aurobindo Pharma Limited

-0.70 (-0.06%)

USD 706.45B
ALKEM:NSE Alkem Laboratories Limited

+86.95 (+1.74%)

USD 599.09B
AJANTPHARM:NSE Ajanta Pharma Limited

+2.15 (+0.09%)

USD 294.04B

ETFs Containing GLENMARK:NSE

SCIF 0.00 % 0.83 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 43.82% 91% A- 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 43.82% 91% A- 82% B
Trailing 12 Months  
Capital Gain 94.41% 86% B+ 76% C+
Dividend Return 0.39% 48% F 27% F
Total Return 94.80% 86% B+ 76% C+
Trailing 5 Years  
Capital Gain 146.14% 48% F 45% F
Dividend Return 2.40% 24% F 22% F
Total Return 148.54% 48% F 44% F
Average Annual (5 Year Horizon)  
Capital Gain 35.68% 58% F 53% F
Dividend Return 36.25% 58% F 52% F
Total Return 0.58% 60% D- 48% F
Risk Return Profile  
Volatility (Standard Deviation) 50.71% 46% F 49% F
Risk Adjusted Return 71.50% 69% C- 58% F
Market Capitalization 343.22B 89% A- 88% B+

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector